TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has required repeat Ranibizumab injections and has had at least 3 injections prior to recruitment~* Informed consent~* Age ≥ 18 years~* Clinical need for a therapeutic ranibizumab intravitreal injection regardless of the medical indication~* Able to understand and read English~Exclusion Criteria:~* Pregnancy (positive pregnancy test)~* Mental disability~* Prisoners~* Patients with fluctuating or impaired decision-making capacity~* Inability to comply with study or follow-up procedures~* Previous reaction to the same drug class

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4% lidocaine (Type: EXPERIMENTAL): Eyes were anesthetized with 0.5% proparacaine and then with three cotton swabs soaked in 4% liquid lidocaine applied with moderate pressure to the site of the injection inferotemporally to the limbus. Each participant was assigned to have this prep during one of the consecutive study visits if unilateral or in one eye if patient requires bilateral injections given the same day
- 3.5% ophthalmic lidocaine gel (Type: EXPERIMENTAL): Eye was anesthetized with 0.5% proparacaine and then with 3.5% ophthalmic lidocaine gel applied to the surface of the eye. Each participant was randomly assigned to receive this preparation during one of two consecutive intravitreal injection (if unilateral disease) or in one eye if requiring bilateral injections given on the same day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* birthweight less than 1500 g~* Age \>7 days~* Free of severe intraventricular hemorrhage (Grade III-IV)~* requiring nasal continuous positive airway pressure with a stable compensated respiratory acidosis (pH 7.25 - 7.45, pCO2 \> 43 mm Hg),~* medically stable.~Exclusion Criteria:~* major congenital anomalies

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- Nasal High Frequency Ventilation (Type: EXPERIMENTAL): Stable infants born at less than 1501 g who are at least 7 days old and undergoing nasal continuous positive airway pressure treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate who have inadequate response to Tumor Necrosis Factor (TNF) inhibitors.~Exclusion Criteria:~* Pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): None
- Sequence 2 (Type: EXPERIMENTAL): None
- Sequence 3 (Type: PLACEBO_COMPARATOR): None
- Sequence 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of pPE in this pregnancy requiring delivery \< 37 weeks gestation: new or worsening hypertension \>20 weeks with proteinuria or other features suggestive of PE (abnormal haematological, biochemical parameters, fetal growth restriction (FGR) and/or abnormal sFlt:PlGF (\>85)).~* Biochemical / haematological cut-offs:~* Platelet count \<100 x109/L~* Alanine amino transferase \> 50units/L~* Creatinine \>90mmol/L~* FGR:~* Abdominal circumference (AC) / estimated fetal weight (EFW) \<3rd centile~* Or 2 of the following:~* AC/EFW \<10th centile~* AC/EFW crossing centiles by \>2 quartiles~* Cerebroplacental ratio \<5th centile~* Umbilical artery PI \>95th centile~* At time of randomisation:~* Postpartum, within 3 days of delivery~* Aged 18 years or over~* Able to provide informed consent~* Serum creatinine \<100 mmol/l~Exclusion Criteria:~* Inability to consent~* Known cardiac disease~* Contraindication to ACE inhibitors~* Renal artery stenosis

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Investigational medicinal product (Type: EXPERIMENTAL): Oral enalapril maleate once daily: 5mg for 1 week, then 10mg for 2 weeks, then 20mg maintenance (for total of 6 months postpartum)
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo once daily for 6 months postpartum
- Observational arm (Type: NO_INTERVENTION): For participants who decline to be take part in the interventional part of the study (decline randomisation to IMP/placebo) however they consent to the observational components of the study (serial echocardiography and biomarkers postpartum).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: South Australian Meningococcal B Vaccine Herd Immunity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* South Australian secondary school students in years 10, 11, and 12 in 2017~* Written parental consent for those under the age of 18~* Written student consent assent for those under the age of 18 (or if 18 years old and older consent for themselves)~* Available at school for at least the first pharyngeal swab and willing to comply with study procedures~Exclusion Criteria:~1. Previous anaphylaxis following any component of Bexsero vaccine~2. Previous receipt of meningococcal B vaccine (Bexsero)~3. Known pregnancy

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
- Group B (Type: NO_INTERVENTION): Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Breast Milk Production With Domperidone in Mothers of Preterm Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* mothers of a preterm infant born \< 30 completed weeks gestation (23 0/7-29 6/7 weeks)~* postpartum period of 7-21 days~* mechanically pumping a minimum average of 6 times a day in the 4-7 days prior to enrollment~* experiencing inadequate milk supply defined as providing \< 100% of the average of the daily nutritional intake during the previous 72-hour period prior to enrollment based on a fluid intake of 250 mL/kg/d or experiencing a clinical reduction of approximately 20% from a peak volume during the previous 72-hour period prior to enrollment~Exclusion Criteria:~* history of known or suspected cardiac dysrhythmias (tachyarrhythmia, Q-Tc prolongation) or currently on an anti-arrhythmic medication~* currently experiencing mastitis~* previous breast surgery, including augmentation or reduction, nipple piercing and/or the use of nipple rings/studs within the last year, or any reduction~* known chronic or debilitating illness, known abnormal liver function or gastric abnormalities gastrointestinal that will be exacerbated by the use of a prokinetic, examples include hemorrhage or blockage, actively treated with acid reflux which requires treatment for greater than 5 days and includes H2 blockers (occasional use of H2 blockers for heartburn or mild acid reflux is not considered an exclusion) and HIV~* known to have a prolactin-releasing pituitary tumor~* receiving medications known to alter the metabolism and pharmacokinetics of domperidone (eg. oral azole antifungals, erythromycin antibiotics, monoamine oxidase inhibitors (MAO) inhibitors) or medications that have dopaminergic or antidopaminergic activity or affect prolactin levels~* mothers of higher order pregnancies (triplet, or more)~* currently smoking 6 or more cigarette per day as reported by the mother

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Domperidone for days 1 to 28 (Type: EXPERIMENTAL): Domperidone maleate tablets 10 mg orally three times daily from days 1 to 28
- Placebo for days 1 to 14 and domperidone for day 15-28 (Type: PLACEBO_COMPARATOR): Identical placebo tablets 10 mg orally three times daily from days 1 to 14 followed by Domperidone maleate tablets 10 mg orally three times daily from days 15 to 28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Stem Cell Therapy in Patients With Autism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children between the ages of 3 and 12 years.~* DSM-IV diagnosis of Autistic Disorder.~* Total score of CARS ≥ 30.~* Parents or legal guardian willing to sign the ICF.~Exclusion Criteria:~* Any history of hypersensitivity to serum products, or other known drug and food allergy.~* History of prior or current DSM-IV psychotic disorder (e.g., schizophrenia, bipolar disorder, other psychosis), Pervasive Developmental Disorder not otherwise specified (PDD NOS), Asperger's, or Rett's.~* History of Epileptic seizure activity in the past 6 months.~* Autism caused by seizure disorders (active), cerebrovascular disease or brain trauma.~* The global autism ratings are assessed as being absent, minimal or mild.~* Existing moderate or severe extrapyramidal symptoms (EPS) or history of tardive dyskinesia.~* Subjects who have displayed significant self-injurious behavior (children who have caused visible harm to themselves).~* HIV+~* Acute and chronic hepatitis.~* Autoimmune disease, e.g. lupus erythematosus, multiple sclerosis.~* Severe pulmonary and hematological disease, malignancy or hypo-immunity.~* Currently undertaking other treatment that may affect the safety/efficacy of stem cells.~* Enrollment in other trials in the last 3 months.~* Other criteria the investigator consider improper for inclusion.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Rehabilitation plus hCB-MNCs treatment (Type: EXPERIMENTAL): Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
- Rehabilitation plus hCB-MNCs and hUC-MSCs therapy (Type: EXPERIMENTAL): Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does the Application of Cold Decreases the Pain Associated in the Pose of a Patch of Capsaicine at High Concentration on the Carrier Patients of Localized Neuropathic Pains ? - DIDOCAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major~* Do not opposing the participation in the study~* Monitoring in the case of localized neuropathic pain~* Diagnostic with neuropathic pain score ≥ 4~* Neuropathic pain conventional treatment failure of first-line~* Front advantage of laying a first patch Qutenza®~* With ability to understand the proposed study~Exclusion Criteria:~* Patch Installation on the feet, face, mucous membranes~* Eutectic mixture of local anesthetics (EMLA) Pose premedication~* Having Already received prior to the installation of a patch of Qutenza®~* Allergy to components Qutenza®~* Known and poorly stabilized hypertension~* Known cryoglobulinaemia~* Pregnant or lactating women~* Patient enjoying a measure of legal protection (guardianship, guardianship ...)~* Private Patient freedom~* No affiliation to a social security scheme.~* Refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Qutenza® without refrigerated cushion (Type: NO_INTERVENTION): Qutenza® without refrigerated cushion
- Qutenza® with refrigerated cushion (Type: EXPERIMENTAL): Qutenza® with refrigerated cushion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent prior to any study-related procedures being performed.~2. Is male or a non-pregnant, non-lactating female aged 18 years or older.~3. Willing and able to follow instructions and be present for the required study visits.~4. Have an Early Treatment Diabetic Retinopathy Study (ETDRS) Best Correct Visual Acuity (BCVA) of 20/200 or better in each eye.~5. Have an Intraocular Pressure (IOP) between 7 and 30 mmHg.~6. Certified as healthy by clinical assessment.~7. Verbal communication skills adequate to participate.~8. Able to tolerate bilateral instillation of Over-The-Counter artificial tear product based on investigator judgement.~Exclusion Criteria:~1. Have participated in an investigational study within the past 30 days.~2. Have a contraindication to local anesthetics.~3. Have known decreased corneal or conjunctival sensitivity.~4. Have had ocular surgery in either eye within the past 90 days.~5. Have had an intravitreal injection in either eye within 14 days.~6. Have ocular disease requiring punctual plugs or ocular inflammation.~7. Are currently using a systemic opioid or opiate analgesic or topical NSAID.~8. Cannot withhold their over the counter (OTC) artificial tear lubricant products for one hour preceding or following study medication.~9. Any condition, including alcohol or drug dependency, that would limit the subject's ability to comply with the procedures of the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AG-920 (Type: EXPERIMENTAL): Articaine Sterile Topical Ophthalmic Solution (AG-920) is a sterile, isotonic, non-preserved aqueous solution containing the active ingredient Articaine HCl 8%, Boric Acid, Mannitol, Sodium Acetate Trihydrate, Glacial Acetic Acid, and Edetate Disodium Dihydrate. The product formulation is adjusted to pH 4.5 to 5.0. Each subject randomized to AG-920 will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo ophthalmic solution is identical to the active product, with the exception of the active ingredient. Each subject randomized to placebo will receive a single dose of 2 drops 30 seconds apart from a single vial into study eye.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-effect Relationship of Low-dose IL-2 in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \[18-50\] years;~* With a T1D:~* Treated with insulin for ≤ 2 years,~* With at least one auto-antibody among: anti-islet, anti-GAD, anti-IA2, anti-ZnT8 ;~* No clinically relevant abnormal value for hematology, biochemistry, liver and kidney function~* Lymphocyte \[1000-4000\]/ mm3~* Informed consent signed by the patient and the investigator before any intervention necessary for the trial.~Exclusion Criteria:~* Contra-indications to IL2 :~* Hypersensibility to IL-2 or its excipients,~* Severe cardiopathy~* Ongoing infection requiring antibiotherapy,~* O2 Saturation ≤ 90 %~* Severe impairment of a vital organ~* Previous organ allograft~* Non authorized concomitant treatment : i.e. immuno-modulators, cytotoxic, drug modifying glycemia~* Cancer progressing or cured for less than 5 years except for primary basal cell carcinoma or carcinoma in situ of the uterine cervix.~* Participation to another clinical investigation in \< 3 months~* Pregnant or lactating women~* Male or female in age of procreation without efficient contraception during the study~* No affiliation to National Health Insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- IL2-4 (Type: PLACEBO_COMPARATOR): None
- IL2-2 (Type: EXPERIMENTAL): 1 millions IU of IL-2 per day
- IL2-3 (Type: EXPERIMENTAL): 3 millions IU of IL-2 per day
- IL2-1 (Type: EXPERIMENTAL): 0.33 millions IU of IL-2 per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Children may be eligible for this study if they:~* Are HIV-positive.~* Are between 3 months and 16 years old (consent of parent or legal guardian required). (These age requirements reflect a change.)~* Have a plasma viral load of at least 400 copies/ml at screening.~* Agree to practice abstinence or use effective methods of birth control during the study.~* Are able to take oral medication and comply with study requirements.~* Are taking at least 1 nucleoside reverse transcriptase inhibitor (NRTI), such as zidovudine (ZDV) or stavudine (d4T). Patients can begin taking NRTIs at the beginning of the study.~Exclusion Criteria~Children will not be eligible for this study if they:~* Have had more than 2 episodes of moderate to severe diarrhea or vomiting lasting more than 4 days within 3 months prior to study entry.~* Are allergic to EFZ or NFV.~* Have any disease, including hepatitis, cancer, or an active opportunistic (HIV-associated) infection.~* Are pregnant or breast-feeding.~* Are taking any other experimental drugs or certain medications.~* Have ever taken protease inhibitors (PIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs).

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed measurable squamous cell carcinoma of the vulvar with an assessable lesion on the vulva or measurable metastatic disease. Tumors may be primary or recurrent. Patients must have plans for surgery or definitive treatment with chemotherapy +/-radiation unless they have measurable metastatic disease.~* 18 years of age or older~* No concurrent chemotherapy or radiotherapy~* NO previous chemotherapy or radiotherapy within the preceding 1 month~* ECOG performance status of 0-1~Exclusion Criteria:~* Known hypersensitivity reaction to erlotinib~* Other coexisting malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma~* Treatment with a non-FDA approved or investigational drug within 30 days~* Persistent toxicities (grade 2 or above) from previous treatment, expect alopecia or lymphedema~* Serum creatinine level greater than CTC grade 2~* Pregnancy or breast feeding~* Severe or uncontrolled systemic disease~* Significant clinical disorder or laboratory finding that makes it potentially unsafe for the subject to participate

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib (Type: EXPERIMENTAL): Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete